# Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury

> **NIH NIH R43** · VERSAPEUTICS INC · 2022 · $495,137

## Abstract

PROJECT SUMMARY/ABSTRACT
 Every year in the United States, approximately 17,800 people suffer acute spinal cord injuries (SCI).
While recent advances in the medical management of SCI have led to improvements in the diagnosis and
stabilization of these patients, there has been minimal progress made towards improving outcomes with current
treatment options. For instance, fewer than 1% of individuals experience complete neurological recovery by the
time of hospital discharge, and the lifetime costs of living with an SCI can average up to $5.1M for individuals
with high tetraplegia. VersaPeutics is a small business that is developing VersaMab-101, a novel monoclonal
antibody therapy for acute SCI. Traditionally, biologic therapeutics for SCI have been delivered intrathecally via
osmatic pump into the spinal cord. Our previously study has demonstrated the stability of VersaMab-101 in one
of the FDA approved programmable pump under a simulated clinic administration. In the present study, we will
examine the pharmacokinetics and efficacy of intrathecally administration of VersaMab-101 by using rodent
models of SCI. At the end of this project, we expect to have high quality datasets that will inform our clinical
development plans for VersaMab-101 and also will be published to help the spinal cord injury drug development
community.

## Key facts

- **NIH application ID:** 10484664
- **Project number:** 1R43NS127712-01
- **Recipient organization:** VERSAPEUTICS INC
- **Principal Investigator:** Miao Sun
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $495,137
- **Award type:** 1
- **Project period:** 2022-04-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10484664

## Citation

> US National Institutes of Health, RePORTER application 10484664, Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury (1R43NS127712-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10484664. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*